Thanks for the reply. You bring up two different i

Thanks for the reply. You bring up two different issues:

1.) PR that feeds the shorts. My position on the shorts won’t be popular here, but we should ignore them. We should manage to long term strategy and catalysts, not the short term stock price.

2.) Trial design and FDA negotiations. The majority of our catalysts moving forward will be dependent on trial design/results and acceptance by the FDA. If other companies are able to negotiate endpoints post trial - we need to do the same. We need to strategically invest in improving our capabilities in this area and do it fast. That may be through hiring the right people, hiring consultants, a BP partnership,.....we better figure it out because a number of significant catalysts depend on it.